Jonathan Yingling
Chief Tech/Sci/R&D Officer en ARCUS BIOSCIENCES, INC. .
Perfil
Jonathan Yingling is currently the Chief Scientific Officer at Arcus Biosciences, Inc. He previously held positions as Vice President-Oncology Discovery at Bristol Myers Squibb Co. from 2013 to 2015, and as Chief Scientific Officer & Senior Vice President at Idera Pharmaceuticals, Inc. from 2018 to 2020.
He also served as the Chief Scientific Officer at DNIB Unwind, Inc. Dr. Yingling completed his undergraduate degree at The College of William & Mary and obtained his doctorate from Duke University School of Medicine in 2016.
Cargos activos de Jonathan Yingling
Empresas | Cargo | Inicio |
---|---|---|
ARCUS BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/01/2020 |
Antiguos cargos conocidos de Jonathan Yingling.
Empresas | Cargo | Fin |
---|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Chief Tech/Sci/R&D Officer | 31/01/2020 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/10/2015 |
DNIB UNWIND INC | Chief Tech/Sci/R&D Officer | - |
Formación de Jonathan Yingling.
The College of William & Mary | Undergraduate Degree |
Duke University School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ARCUS BIOSCIENCES, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
DNIB Unwind, Inc.
DNIB Unwind, Inc. BiotechnologyHealth Technology DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Jonathan Yingling